文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

危机时期应使用转运呼吸机吗?紧急授权的非传统呼吸机使用与COVID-19急性呼吸窘迫综合征患者死亡率相关

Should Transport Ventilators Be Used in Times of Crisis? The Use of Emergency Authorized Nonconventional Ventilators Is Associated With Mortality Among Patients With COVID-19 Acute Respiratory Distress Syndrome.
PubMed 文献 · Crit Care Med · 2024-04-02
一句话结论在COVID-19 ARDS插管患者中,全程仅用非传统呼吸机与28天院内死亡率升高相关(OR 1.41,95%CI 1.07-1.86),作者认为储备应优先配置全功能ICU呼吸机而非非传统呼吸机。

该多中心回顾性观察研究纳入2020年3月1日至4月30日纽约单一医疗系统内因COVID-19 ARDS插管的患者,评估全程仅使用非传统呼吸机(转运呼吸机和某些无创正压装置)与28天院内死亡率的关系。多变量logistic回归显示,全程仅用非传统呼吸机与更高的28天院内死亡率相关(OR 1.41,95%CI 1.07-1.86);倾向性评分匹配分析中,非传统呼吸机组死亡率为68.9%,对照组为60.7%(P=0.02)。作者结论认为非传统呼吸机的使用与COVID-19 ARDS患者死亡率升高相关,未来呼吸机短缺时若储备更多全功能ICU呼吸机而非非传统呼吸机,可能挽救更多生命。

要点

  • 在纽约单一医疗系统2020年3月1日至4月30日因COVID-19 ARDS插管的患者中,全程仅使用非传统呼吸机与更高的28天院内死亡率独立相关(OR 1.41,95%CI 1.07-1.86)。
  • 倾向性评分匹配分析中,全程仅用非传统呼吸机者死亡率为68.9%,对照组为60.7%(P=0.02)。
  • 非传统呼吸机包括转运呼吸机和某些无创正压装置。
  • 作者认为,未来呼吸机短缺时,国家和地方储备中配置更多全功能ICU呼吸机而非非传统呼吸机,可能挽救更多生命。

适用人群与场景

  • 2020年3月1日至4月30日期间,纽约单一医疗系统内因COVID-19 ARDS插管的患者。

研究设计与关键结果

  • 研究类型:多中心回顾性观察研究;样本来源:纽约单一医疗系统;招募期:2020年3月1日至2020年4月30日;人群:因COVID-19 ARDS插管的患者;干预:无。
  • 主要终点为28天院内死亡率。多变量logistic回归显示,全程仅使用非传统呼吸机与更高的28天院内死亡率相关(OR 1.41,95%CI 1.07-1.86)。
  • 倾向性评分匹配分析中,全程仅用非传统呼吸机者死亡率为68.9%,对照组为60.7%(P=0.02)。

证据类型、等级与局限

  • 证据类型:多中心回顾性观察研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,非传统呼吸机的使用与COVID-19 ARDS患者死亡率升高相关;未来呼吸机短缺时,若在国家和地方储备中配置更多全功能ICU呼吸机而非非传统呼吸机,可能挽救更多生命。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Nonconventional ventilators (NCVs), defined here as transport ventilators and certain noninvasive positive pressure devices, were used extensively as crisis-time ventilators for intubated patients with COVID-19. We assessed whether there was an association between the use of NCV and higher mortality, independent of other factors.

DESIGN: This is a multicenter retrospective observational study.

SETTING: The sample was recruited from a single healthcare system in New York. The recruitment period spanned from March 1, 2020, to April 30, 2020.

PATIENTS: The sample includes patients who were intubated for COVID-19 acute respiratory distress syndrome (ARDS).

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: The primary outcome was 28-day in-hospital mortality. Multivariable logistic regression was used to derive the odds of mortality among patients managed exclusively with NCV throughout their ventilation period compared with the remainder of the sample while adjusting for other factors. A secondary analysis was also done, in which the mortality of a subset of the sample exclusively ventilated with NCV was compared with that of a propensity score-matched subset of the control group. Exclusive use of NCV was associated with a higher 28-day in-hospital mortality while adjusting for confounders in the regression analysis (odds ratio, 1.41; 95% CI [1.07-1.86]). In the propensity score matching analysis, the mortality of patients exclusively ventilated with NCV was 68.9%, and that of the control was 60.7% ( p = 0.02).

CONCLUSIONS: Use of NCV was associated with increased mortality among patients with COVID-19 ARDS. More lives may be saved during future ventilator shortages if more full-feature ICU ventilators, rather than NCVs, are reserved in national and local stockpiles.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Gondhalekar VB, Gandomi A, Gilman SL, et al. Should Transport Ventilators Be Used in Times of Crisis? The Use of Emergency Authorized Nonconventional Ventilators Is Associated With Mortality Among Patients With COVID-19 Acute Respiratory Distress Syndrome. Crit Care Med. 2024. PMID: 38563609. doi:10.1097/CCM.0000000000006252

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。